New imaging agent for advanced solid tumors
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new imaging agent (18F-TRX) to see if it can better detect cancer spread in people with advanced solid tumors. It is designed for patients with specific cancers like high-grade brain tumors, advanced kidney cancer, or prostate cancer that has stopped responding to hormone therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of advanced cancer that has spread to other parts of the body (like brain tumors, kidney cancer, or prostate cancer that no longer responds to hormone therapy).
- You are able to do most daily activities without help (fully active or limited to light work).
- Your blood counts and organ function (liver, kidneys) are within certain safe levels.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of PET scan that uses a special antibody to find a marker called Trop2 on many common solid tumors. It may help doctors see tumors more clearly without needing a biopsy.
This study tests a new imaging agent that helps PET scans show cancer more clearly. It may help doctors see where cancer is in your body and plan your treatment better.
This study tests whether a new imaging agent called 68Ga-MY6349 can help detect tumors during a PET/CT scan. If you are an adult with a solid tumor (newly diagnosed or already treated), you may be able to take part in this research to see if the new tracer works better than standard imaging.
This trial tests a special imaging agent (a nanobody probe) that targets a protein called CD147 on tumor cells. If you have a solid tumor like melanoma, liver, colorectal, pancreatic, breast, stomach, or lung cancer, the PET scan may help doctors see your cancer more clearly.
This early-stage trial tests a new radioactive tracer called [68Ga]Ga-R54 that helps doctors see certain advanced cancers (like breast, lung, colon, ovary, pancreas, or multiple myeloma) on PET scans. The tracer targets a specific protein (CXCR4) found on cancer cells, which may help doctors better detect and understand your cancer.
This trial tests a new imaging agent that may help doctors see tumors more clearly during a PET scan. It could help diagnose cancer or check if it has returned after treatment.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.